Logo image of XOMAP

XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Fundamental Analysis

USA - NASDAQ:XOMAP - US98419J3059

26.12 USD
-0.16 (-0.63%)
Last: 9/30/2025, 9:34:44 AM
Fundamental Rating

4

XOMAP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. XOMAP has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMAP is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year XOMAP has reported negative net income.
XOMAP had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMAP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMAP reported negative operating cash flow in multiple years.
XOMAP Yearly Net Income VS EBIT VS OCF VS FCFXOMAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.93%, XOMAP belongs to the top of the industry, outperforming 85.07% of the companies in the same industry.
XOMAP has a Return On Equity of -19.17%. This is amongst the best in the industry. XOMAP outperforms 85.26% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.73%, XOMAP belongs to the top of the industry, outperforming 91.79% of the companies in the same industry.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAP Yearly ROA, ROE, ROICXOMAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

Looking at the Operating Margin, with a value of 21.23%, XOMAP belongs to the top of the industry, outperforming 94.96% of the companies in the same industry.
The Profit Margin and Gross Margin are not available for XOMAP so they could not be analyzed.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAP Yearly Profit, Operating, Gross MarginsXOMAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMAP is destroying value.
Compared to 1 year ago, XOMAP has more shares outstanding
The number of shares outstanding for XOMAP has been increased compared to 5 years ago.
XOMAP has a worse debt/assets ratio than last year.
XOMAP Yearly Shares OutstandingXOMAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAP Yearly Total Debt VS Total AssetsXOMAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMAP has an Altman-Z score of -5.45. This is a bad value and indicates that XOMAP is not financially healthy and even has some risk of bankruptcy.
XOMAP has a Altman-Z score of -5.45. This is in the lower half of the industry: XOMAP underperforms 61.94% of its industry peers.
A Debt/Equity ratio of 1.11 is on the high side and indicates that XOMAP has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.11, XOMAP is doing worse than 77.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -5.45
ROIC/WACC0.36
WACC10.36%
XOMAP Yearly LT Debt VS Equity VS FCFXOMAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.88 indicates that XOMAP has no problem at all paying its short term obligations.
The Current ratio of XOMAP (4.88) is comparable to the rest of the industry.
XOMAP has a Quick Ratio of 4.88. This indicates that XOMAP is financially healthy and has no problem in meeting its short term obligations.
XOMAP has a Quick ratio (4.88) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMAP Yearly Current Assets VS Current LiabilitesXOMAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for XOMAP have decreased strongly by -38.74% in the last year.
Looking at the last year, XOMAP shows a very strong growth in Revenue. The Revenue has grown by 168.71%.
Measured over the past years, XOMAP shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

XOMAP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.32% yearly.
The Revenue is expected to grow by 35.53% on average over the next years. This is a very strong growth
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMAP Yearly Revenue VS EstimatesXOMAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMAP Yearly EPS VS EstimatesXOMAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMAP. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 50.88, the valuation of XOMAP can be described as expensive.
Based on the Price/Forward Earnings ratio, XOMAP is valued cheaper than 88.62% of the companies in the same industry.
XOMAP's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.13.
Industry RankSector Rank
PE N/A
Fwd PE 50.88
XOMAP Price Earnings VS Forward Price EarningsXOMAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XOMAP indicates a rather cheap valuation: XOMAP is cheaper than 91.79% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.93
XOMAP Per share dataXOMAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

XOMAP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMAP's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.97%
EPS Next 3Y37.32%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 8.20%, XOMAP is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 170.03, XOMAP pays a better dividend. On top of this XOMAP pays more dividend than 99.63% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, XOMAP pays a better dividend.
Industry RankSector Rank
Dividend Yield 8.2%

5.2 History

XOMAP has been paying a dividend for over 5 years, so it has already some track record.
XOMAP has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAP Yearly Dividends per shareXOMAP Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

XOMAP has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-30.88%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
XOMAP Yearly Income VS Free CF VS DividendXOMAP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

More info and screens

XOMA ROYALTY CORP - XOMA 8 5/8 PERP

NASDAQ:XOMAP (9/30/2025, 9:34:44 AM)

26.12

-0.16 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners68.05%
Inst Owner ChangeN/A
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap315.79M
Analysts82
Price Target52.65 (101.57%)
Short Float %0.05%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield 8.2%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years3
Ex-Date07-03 2025-07-03 (0.53906)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)-23.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)78.18%
EPS NY rev (1m)52.1%
EPS NY rev (3m)198.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)3.63%
Revenue NY rev (3m)10.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 50.88
P/S 7.03
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 6.72
EV/EBITDA 30.93
EPS(TTM)-1.54
EYN/A
EPS(NY)0.51
Fwd EY1.97%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -5.45
F-Score5
WACC10.36%
ROIC/WACC0.36
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.34%
EBIT Next 3Y51.87%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A